免疫疗法在肉瘤治疗中的新兴作用。
The emerging role of immunotherapy for the treatment of sarcoma.
机构信息
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
出版信息
J Surg Oncol. 2021 Mar;123(3):730-738. doi: 10.1002/jso.26306. Epub 2020 Dec 1.
Abstract
Clinicians caring for patients with sarcoma founded the field of cancer immunotherapy. Despite this, contemporary success with immunotherapy for sarcoma has been limited. Here, we review immunotherapy for sarcoma including Coley's toxins, interleukin-2, adoptive cell transfer, and checkpoint blockade. We detail recent and ongoing efforts to combine checkpoint blockade with other immune modulators, surgery, or radiation. These results, along with ongoing investigations, have identified immunotherapeutic approaches as a promising avenue for progress in advanced sarcomas.
摘要
临床医生在治疗肉瘤患者的过程中开创了癌症免疫治疗领域。尽管如此，肉瘤免疫治疗在当代的应用仍然受到限制。本文综述了肉瘤的免疫治疗方法，包括科利毒素、白细胞介素-2、过继细胞转移和检查点阻断。我们详细介绍了近期和正在进行的将检查点阻断与其他免疫调节剂、手术或放疗相结合的努力。这些结果以及正在进行的研究表明，免疫治疗方法是晚期肉瘤取得进展的一个有前途的途径。
相似文献
1
The emerging role of immunotherapy for the treatment of sarcoma.免疫疗法在肉瘤治疗中的新兴作用。
J Surg Oncol. 2021 Mar;123(3):730-738. doi: 10.1002/jso.26306. Epub 2020 Dec 1.
2
Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.免疫疗法：软组织和骨肉瘤治疗的新（和旧）方法。
Oncologist. 2018 Jan;23(1):71-83. doi: 10.1634/theoncologist.2016-0025. Epub 2017 Sep 21.
3
Immunotherapy in Sarcoma: Future Horizons.肉瘤的免疫疗法：未来展望
Curr Oncol Rep. 2015 Nov;17(11):52. doi: 10.1007/s11912-015-0476-7.
4
Sarcomas: Immune biomarker expression and checkpoint inhibitor trials.肉瘤：免疫生物标志物表达和检查点抑制剂试验。
Cancer Treat Rev. 2020 Dec;91:102115. doi: 10.1016/j.ctrv.2020.102115. Epub 2020 Oct 20.
5
Immunotherapeutic approaches to sarcoma.肉瘤的免疫治疗方法。
Curr Treat Options Oncol. 2015 Jun;16(6):26. doi: 10.1007/s11864-015-0345-5.
6
Potential for immunotherapy in soft tissue sarcoma.软组织肉瘤免疫治疗的潜力。
Hum Vaccin Immunother. 2014;10(11):3117-24. doi: 10.4161/21645515.2014.983003.
7
The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas.威廉·B·科利毒素与骨和软组织肉瘤的治疗
Iowa Orthop J. 2006;26:154-8.
8
From vision to reality: deploying the immune system for treatment of sarcoma.从愿景到现实：利用免疫系统治疗肉瘤
Discov Med. 2017 Jan;23(124):61-74.
9
The current landscape of early drug development for patients with sarcoma in the immunotherapy era.免疫治疗时代肉瘤患者早期药物开发的现状。
Future Oncol. 2018 May;14(12):1197-1211. doi: 10.2217/fon-2017-0565. Epub 2018 Apr 27.
10
Immunotherapy in soft-tissue sarcoma.软组织肉瘤的免疫治疗。
Curr Oncol. 2020 Feb;27(Suppl 1):17-23. doi: 10.3747/co.27.5407. Epub 2020 Feb 1.
引用本文的文献
1
Heterogeneity in response to neoadjuvant radiotherapy between soft tissue sarcoma histotypes: associations between radiology and pathology findings.软组织肉瘤组织学类型对新辅助放疗反应的异质性：放射学与病理学结果之间的关联
Eur Radiol. 2025 Mar;35(3):1337-1350. doi: 10.1007/s00330-024-11258-6. Epub 2024 Dec 19.
2
Trends in the use of immunotherapy to treat soft tissue sarcoma.免疫疗法治疗软组织肉瘤的应用趋势。
Am J Surg. 2024 Oct;236:115794. doi: 10.1016/j.amjsurg.2024.115794. Epub 2024 Jun 5.
3
Harnessing ferroptosis for enhanced sarcoma treatment: mechanisms, progress and prospects.利用铁死亡增强肉瘤治疗：机制、进展与展望
Exp Hematol Oncol. 2024 Mar 12;13(1):31. doi: 10.1186/s40164-024-00498-3.
4
Sarcoma Immunotherapy: Confronting Present Hurdles and Unveiling Upcoming Opportunities.肉瘤免疫疗法：直面当前障碍，揭示未来机遇。
Mol Cells. 2023 Oct 31;46(10):579-588. doi: 10.14348/molcells.2023.0079. Epub 2023 Sep 22.
5
ATRX loss suppresses the type I interferon response in sarcoma cells through chromatin remodeling.ATRX缺失通过染色质重塑抑制肉瘤细胞中的I型干扰素反应。
Am J Cancer Res. 2023 Aug 15;13(8):3547-3558. eCollection 2023.
6
Undifferentiated and Dedifferentiated Metastatic Melanomas Masquerading as Soft Tissue Sarcomas: Mutational Signature Analysis and Immunotherapy Response.未分化和去分化转移性黑色素瘤伪装成软组织肉瘤：突变特征分析和免疫治疗反应。
Mod Pathol. 2023 Aug;36(8):100165. doi: 10.1016/j.modpat.2023.100165. Epub 2023 Mar 27.
7
The Landscape of Immunotherapy for Retroperitoneal Sarcoma.免疫治疗腹膜后肉瘤的全景。
Curr Oncol. 2023 Feb 9;30(2):2144-2158. doi: 10.3390/curroncol30020165.
8
Cancer-Associated B Cells in Sarcoma.肉瘤中与癌症相关的B细胞
Cancers (Basel). 2023 Jan 19;15(3):622. doi: 10.3390/cancers15030622.
9
VISTA in Soft Tissue Sarcomas: A Perspective for Immunotherapy?软组织肉瘤中的VISTA：免疫治疗的前景？
Cancers (Basel). 2022 Feb 16;14(4):1006. doi: 10.3390/cancers14041006.
10
Long-term Follow-up and Patterns of Response, Progression, and Hyperprogression in Patients after PD-1 Blockade in Advanced Sarcoma.PD-1 阻断治疗晚期肉瘤患者的长期随访及反应、进展和超进展模式。
Clin Cancer Res. 2022 Mar 1;28(5):939-947. doi: 10.1158/1078-0432.CCR-21-3445.
本文引用的文献
1
A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma.厄帕卡他司他联合帕博利珠单抗治疗晚期肉瘤的 II 期研究。
Clin Cancer Res. 2023 Jun 1;29(11):2043-2051. doi: 10.1158/1078-0432.CCR-22-3911.
2
Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02).贝姆培加德白介素（NKTR - 214）联合纳武利尤单抗治疗晚期实体瘤患者：安全性、疗效及免疫激活的I期剂量递增研究（PIVOT - 02）
Cancer Discov. 2020 Aug;10(8):1158-1173. doi: 10.1158/2159-8290.CD-19-1510. Epub 2020 May 21.
3
Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial.多柔比星联合奥拉单抗对比多柔比星联合安慰剂治疗晚期软组织肉瘤患者的生存影响：ANNOUNCE 随机临床试验。
JAMA. 2020 Apr 7;323(13):1266-1276. doi: 10.1001/jama.2020.1707.
4
Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma.转移性肢端、黏膜和葡萄膜黑色素瘤使用检查点抑制剂后的生存情况。
J Immunother Cancer. 2020 Mar;8(1). doi: 10.1136/jitc-2019-000341.
5
Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies.基因组学、形态蛋白质组学与肺泡软组织肉瘤患者的治疗模式及对多种实验性治疗的反应。
Mol Cancer Ther. 2020 May;19(5):1165-1172. doi: 10.1158/1535-7163.MCT-19-0579. Epub 2020 Mar 3.
6
Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial.接受替莫唑胺联合替莫唑胺治疗的局部晚期或转移性肉瘤患者的客观缓解率：一项 2 期临床试验。
JAMA Oncol. 2020 Mar 1;6(3):402-408. doi: 10.1001/jamaoncol.2019.6152.
7
B cells are associated with survival and immunotherapy response in sarcoma.B 细胞与肉瘤的生存和免疫治疗反应有关。
Nature. 2020 Jan;577(7791):556-560. doi: 10.1038/s41586-019-1906-8. Epub 2020 Jan 15.
8
Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma.免疫检查点抑制剂治疗后的失败模式可预测转移性黑色素瘤局部治疗后持久的无进展生存期。
J Immunother Cancer. 2019 Jul 24;7(1):196. doi: 10.1186/s40425-019-0672-3.
9
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.依匹单抗联合帕博利珠单抗对比安慰剂联合帕博利珠单抗用于不可切除或转移性黑色素瘤患者（ECHO-301/KEYNOTE-252）：一项 III 期、随机、双盲研究。
Lancet Oncol. 2019 Aug;20(8):1083-1097. doi: 10.1016/S1470-2045(19)30274-8. Epub 2019 Jun 17.
10
Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial.阿昔替尼联合帕博利珠单抗治疗包括腺泡状软组织肉瘤在内的晚期肉瘤患者：一项单中心、单臂、Ⅱ期临床试验。
Lancet Oncol. 2019 Jun;20(6):837-848. doi: 10.1016/S1470-2045(19)30153-6. Epub 2019 May 8.
Zotero 插件